Acute Bacterial Skin And Skin Structure Infections Market Global Report 2026 Market Outlook 2026–2030 Exploring New Business Opportunities
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Growth Is Projected For The Acute Bacterial Skin And Skin Structure Infections Market During The Forecast Period 2026–2030?
The acute bacterial skin and skin structure infections market size has shown significant expansion in recent years. It is anticipated to increase from $12.9 billion in 2025 to $14.09 billion in 2026, registering a compound annual growth rate (CAGR) of 9.2%. The historical growth of this market is attributable to the constrained availability of broad-spectrum antibiotics, a rise in the prevalence of hospital-acquired infections, heightened awareness regarding complications from skin infections, improved access to community healthcare, and the widespread adoption of standard infection control protocols.
The acute bacterial skin and skin structure infections market is anticipated to experience substantial growth over the coming years, with its valuation expected to reach $20.79 billion by 2030, advancing at a compound annual growth rate (CAGR) of 10.2%. This projected expansion is primarily fueled by the progression in next-generation antibiotics, increased financial commitment to antimicrobial research, the proliferation of community-based infection management programs, the expansion of hospital pharmacy distribution channels, and the deployment of rapid diagnostic technologies. Notable trends for the forecast duration include a rise in the incidence of acute bacterial skin and skin structure infections, the increasing uptake of new antibiotics and combination therapies, the enlargement of hospital and community healthcare facilities, a growing application of oral and parenteral antibiotics, and an intensified focus on mitigating hospital-acquired infection rates.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13282&type=smp
What Underlying Factors Are Accelerating The Growth Of The Acute Bacterial Skin And Skin Structure Infections Market?
The increasing occurrence of skin infections is anticipated to boost the acute bacterial skin and skin structure infections market in the future. Skin infections are medical conditions where microorganisms like bacteria, fungi, or viruses invade and proliferate within the skin, resulting in various symptoms and discomfort. This increase in skin infections generates a greater need for therapeutic remedies, antibiotics, and advanced treatments to address acute bacterial and skin structure infections, ensuring patients receive the highest possible care and outcomes. For instance, data from March 2023, provided by the World Health Organization, a specialized agency of the United Nations based in Switzerland, indicates that approximately 1.8 billion people worldwide experience skin conditions at any given time. Among these, neglected tropical diseases (NTDs) account for roughly 10%, fungal infections for 34%, and bacterial infections for 23%, frequently leading to high mortality rates. Consequently, the growing prevalence of skin infections will stimulate the expansion of the acute bacterial skin and skin structure infections market.
What Market Segments Are Evaluated Within The Acute Bacterial Skin And Skin Structure Infections Market?
The acute bacterial skin and skin structure infections market covered in this report is segmented –
1) By Type Of Infection: Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections, Community-Acquired Acute Bacterial Skin And Skin Structure Infections
2) By Active Ingredients: Delafloxacin, Vancomycin, Ceftaroline Fosamil, Oritavancin, Tedizolid, Daptomycin, Tigecycline, Linezolid, Other Active Ingredients
3) By Route Of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections (HABSSSIs): Surgical Site Infections, Catheter-Related Infections, Infections Related To Medical Devices
2) By Community-Acquired Acute Bacterial Skin And Skin Structure Infections (CABSSSIs): Cellulitis, Abscesses, Impetigo, Folliculitis, Wound Infections
What Industry Trends Are Redefining The Acute Bacterial Skin And Skin Structure Infections Market?
Leading companies in the acute bacterial skin and skin structure infections market are concentrating on developing innovative single-dose therapies, such as Dalbonova, to gain a competitive advantage. Dalbonova serves as a single-dose treatment, offering both convenience and efficacy, enabling patients to achieve desired results with just one potent 1500 mg dose administered once. For instance, in August 2023, BDR Pharmaceuticals International Pvt. Ltd., an India-based pharmaceutical company specializing in API (active pharmaceutical ingredient) and formulation therapeutic segments, including acute bacterial skin and skin structure infections, introduced Dalbonova injection, a single-dose therapy for acute bacterial skin and skin structure infections (ABSSSI). Dalbonova Injection lowers the risk of hospital-acquired diseases by providing a single-dose treatment and removing the requirement for hospital admissions. It is formulated to treat acute bacterial skin and skin structure infections (ABSSSI) resulting from specific gram-positive microorganisms in patients across all age groups, including newborns.
Who Are The Top Market Participants Influencing The Acute Bacterial Skin And Skin Structure Infections Market?
Major companies operating in the acute bacterial skin and skin structure infections market are Pfizer Inc., AbbVie Inc., Novartis AG, GSK PLC, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Aurobindo Pharma Limited, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, Aspen Pharmacare Holdings Limited, Melinta Therapeutics LLC, Abbott Laboratories, Fresenius SE & Co. KGaA, Menarini Group
Read the full acute bacterial skin and skin structure infections market report here:
Which Region Is Projected To Dominate The Acute Bacterial Skin And Skin Structure Infections Market During The Forecast Period?
Asia-Pacific was the largest region in the acute bacterial skin and skin structure infections market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the acute bacterial skin and skin structure infections market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Acute Bacterial Skin And Skin Structure Infections Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=13282&type=smp
Browse Through More Reports Similar to the Global Acute Bacterial Skin And Skin Structure Infections Market 2026, By The Business Research Company
complicated skin and skin structure infections drugs global market report
antimicrobial medical device coatings global market report
Dermatitis Drugs Global Market Report
https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
